Blog

October, 2014: Matriks Biotek Introduces Eagle Biosciences, Inc. as Distributor in North America

MMAE Antibody Drug Conjugate (ADC) ELISA Assay Kit

 

 

Eagle Biosciences recently announced a North American distribution agreement with Matriks Biotek. Matriks develops and manufactures unique ELISA test kits and monoclonal antibodies with a strong focus on meeting research needs and creating products to better understand a variety of diseases and conditions in areas such as inflammation, immunology, gastrology, oncology, diabetes and obesity, and reproductive science.

“Matriks Biotek products bring a multitude of esoteric products to EagleBio.” said Dan Keefe President of EagleBio. He continued, “This is a great collaboration with respect to EagleBio’s goals to continually seek out quality, unique scientific tools and Matriks Biotek’s quest for R&D innovations and special interest for biotherapeutics and novel markers for diseases.” Keefe continued, “We are especially excited about Matriks’ Shikari® ELISA kits and anti-drug antibody ELISA assay kit product line.” He continued, “These can be efficiently used, for monitoring serum trough levels and the presence of anti-drug antibodies respectively.”

These products are currently for research use only. Check out the list of Matrik Biotek products below. Visit the Eagle website www.EagleBio.com or call 866-411-8023 for full details.

Infliximab (Remicade®) Antibodies ELISA Assay kit

Free Adalimumab (Humira®) ELISA Assay Kit

Adalimumab (Humira®) Antibodies ELISA Assay Kit

Etanercept (Enbrel®) ELISA Assay Kit

Etanercept (Enbrel®) Antibodies ELISA Assay Kit

Bevacizumab (Avastin®) ELISA Assay Kit

Bevacizumab (Avastin®) Antibodies ELISA Assay Kit

Trastuzumab (Herceptin®, Herclon®).ELISA Assay Kit

Trastuzumab (Herceptin®, Herclon®) Antibodies ELISA Assay Kit

 

New Study Focuses On Designing Novel Antibodies to Target Breast Cancer Cells


image from www.pinkribbonblues.org

In honor of breast cancer awareness month, we thought we would
share some interesting and hopeful new research. But before discussing
this we should take some time to reflect on the fact that people
afflicted by this disease are battling it everyday and some for
several years. It does seem trivial to only recognize it one month of
every year when you consider all of this, but perhaps this is our way of
setting time aside to focus attention and in some way bring energy,
good vibes, and perhaps fresh ideas to conquer this disease.

A recent study done by the University of Michigan focused on
selecting novel monoclonal antibodies with anticancer activity. They
did this by creating an environment of cancer cells in vitro and then
exposing these cells to numerous antibodies to evaluate if these
antibodies have any anti-cancer fighting effects. How they created the
antibodies is rather intriguing. Read more
.

Sensitivity of Islet Cell Antibodies (ICA) ELISA Compared with Indirect Immunofluorescence Assay

Type 1 diabetes, also known as insulin-dependent diabetes mellitus, results from a chronic autoimmune process which destructs the insulin-secreting pancreatic beta cells. Before the onset of disease T1D patients may demonstrate autoantibodies against different autoantigens of islet cells. Research indicates that these autoantibodies have been shown to be important markers for the identification of individuals with an increased risk to develop T1D at a time when all metabolic tests available still show normal results.

Islet cell autoantibodies detected by indirect immunofluorescence (IIF) have been the first serological markers described for T1D. This technique using tissue sections from human or primate pancreas, however, still reveals methodological problems, especially with regard to inter-laboratory standardization. After discovery of the two main protein antigens of ICA – the enzyme glutamic acid decarboxylase (GAD65) and the islet cell protein IA2 – it has been possible to measure these specific autoantibodies by radioligand assays and recently by sensitive ELISA.

Risk assessment of T1D can be achieved by the combination of tests for these different autoantibodies. Therefore, the Eagle Biosciences ICA screen ELISA Assay kit – designed for the semiquantitative determination of ICA to enable reliable screening – was compared with IIF as the routine method for the detection of ICA.


Conclusion:

The Eagle Biosciences ICA screen ELISA Assay Kit is a robust and sensitive tool for the detection of ICA. In comparison with established methods for the detection of ICA, this assay showed superior sensitivity. These data strongly support further investigation to confirm the better sensitivity of the ICA screen ELISA.

 

 

  • READ Entire AACC Scientific Poster Presentation HERE
  • Review Eagle Biosciences ICA Screen ELISA Assay Kit Product Page
New Discovery that Makes Growing Replacement Organs a Possibility

The
very thought of being able to grow actual human organs in a laboratory is mind
blowing! There are endless possibilities
for medical research with a recent study performed at the MRC Centre of
Regenerative Medicine in Edinburgh, U.K. Scientists were successfully able to cultivate living cells from an
animal in vitro. The process that they used to do this could
be used for a multitude of medical purposes and therapies for transplant
patients and more. This study was
focused on creating a functional thymus for mice but it brings hope that this process could be
used for humans for creating a variety of other organ tissues. Read more.

Credit: MRC Centre for Regenerative Medicine, University of Edinburgh

New Promotion Available Through the End of October for Catecholamine Assays:

 

 

Dopamine Sensitive ELISA

For
the quantitative and very sensitive determination of dopamine in
biological samples including serum, plasma, tissue, and cell culture
samples. Also appropriate for mouse/rat samples. Sample sizes as small
as 20µl with detection limits to 5.9 pg/mL.

Noradrenaline Sensitive ELISA

For
the quantitative and very sensitive determination of noradrenaline in
biological samples including serum, plasma, tissue, and cell culture
samples or even mouse/rat samples. Sample sizes as small as 20µl with
detection limits to 1.0 pg/mL.

Adrenaline Sensitive ELISA

For
the quantitative and very sensitive determination of adrenaline in
biological samples including serum, plasma, tissue, and cell culture
samples and even rodent samples. Sample sizes as small as 20µl with
detection limits to 1.6 pg/mL. 

Serotonin Sensitive ELISA

The Serotonin Ultrasensitive ELISA Assay Kit
provides materials for the quantitative measurement of serotonin in low
concentrated samples, for small sample volumes or for many different
species samples.

These
catecholamine kits have been successfully utilized in many different
species and sample types. Please contact Eagle Biosciences at info@eaglebio.com or 617-419-2019 for details.

Other Catecholamine Assay kits from Eagle Biosciences:

 

  • VMA ELISA
  • HVA ELISA
  • Adrenaline ELISA
  • Dopamine ELISA
  • Noradrenaline ELISA

 

Pancreatic
cancer still continues to have a bleak prognosis despite many advances in
chemotherapy and surgical procedures .In
fact, pancreatic cancer has the worst survival rate of all cancers with only a
small percentage surviving over 5 years after diagnosis. Now, researchers at
the University of Missouri have discovered that a molecule that can used as a
communication system by bacteria can be manipulated to prevent cancer cells
from not only spreading but possibly killing them all together. Read more This
study demonstrated that using such a molecule to combat cancer decreases cell
viability, promotes apoptosis by activating caspases, and inhibits the wound
healing process. It shows amazing
promise for pancreatic cancer however, further research is needed in vivo. Read more

Funding
for pancreatic cancer has increased over the last several years yet it still
only gets one percent of research funding. How is this possible…one of the most
deadly cancers receives only ONE PERCENT of funding?!  Pancreatic cancer is severely underfunded
just like Alzheimer’s as we mentioned in one of our previous blogs, 10 Reasons to Keep with your Vitamin D Levels. We
chose to highlight this new pancreatic cancer research in this blog not only
because it is a significant step towards a cure but also because some folks
from Eagle Biosciences will be walking this weekend in the New England Pancreatic Research Walk in
support of the cause and to support a friend who has lost a loved one.

Lustgarten Foundation is
a private foundation created by Cablevision to
dedicate funding pancreatic research. Cablevision underwrites all of the
foundations costs so that 100% of every donation goes to this research. If you
want to donate to the Lustgarten Foundation Click here or
to donate to the personal cause that we walk for this weekend Click here.

Image from www.sciencedaily.com

 

 

 

 

New Technology:  Aqueous Two Phase System Patterning of Dectection Antibody Solutions for Cross-Reaction Free Multiplex ELISA

Accurate disease diagnosis, patient stratification and biomarker validation require the analysis of multiple biomarkers. This paper describes cross-reactivity-free multiplexing of enzyme-linked immunosorbent assays (ELISAs) using aqueous two-phase systems (ATPSs) to confine detection antibodies at specific locations in fully aqueous environments. Antibody cross-reactions are eliminated because the detection antibody solutions are co-localized only to corresponding surface-immobilized capture antibody spots. This multiplexing technique is validated using plasma samples from allogeneic bone marrow recipients. Patients with acute graft versus host disease (GVHD), a common and serious condition associated with allogeneic bone marrow transplantation, display higher mean concentrations for four multiplexed biomarkers (HGF, elafin, ST2 and TNFR1) relative to healthy donors and transplant patients without GVHD. The antibody co-localization capability of this technology is particularly useful when using inherently cross-reactive reagents such as polyclonal antibodies, although monoclonal antibody cross-reactivity can also be reduced. Because ATPS-ELISA adapts readily available antibody reagents, plate materials and detection instruments, it should be easily transferable into other research and clinical settings.

A brand new device, a blood cleansing
machine developed by bioengineers at Harvard’s Wyss Institute has proven to be
effective in clearing the bloodstream of deadly pathogens.The device, also known as the “artificial spleen”
works by running whole blood through a single bio-spleen unit in vitro. It
utilizes protein-coated nanobeads and magnets to bind to sugar molecules on the
surfaces of over 90 different pathogens including bacteria, viruses and
fungi.  Read more 

This is fascinating research as this device may prove to
fulfill the insurmountable need of combating antibiotic resistant
pathogens. Ebola, watch out…with
continued progress in this research your days may be numbered!   Read more

image from new.softpedia.com

September 2014: Eagle Biosciences Introduces New Antibodies from ImmuSmol

September 16, 2014: Eagle Biosciences recently announced a North American distribution agreement with ImmuSmol, Inc. of France. ImmuSmol develops and manufactures research antibodies and esoteric assays in a variety of research fields. They strive to be the best in the industry by selecting antibodies for their specificity and binding affinity by ELISA and systematically validating for IHC.They have a strong expertise in antigen design and a solid focus for targeting low molecular weight molecules which are not typically addressed by antibodies such as amino acid metabolites, lipids, saccharides, toxins, pesticide residues, and small molecule drugs.

“ImmuSmol products bring tremendous value to EagleBio and more specifically our line of antibodies.” said Dan Keefe President of EagleBio. He continued, “A partnership with ImmuSmol provides us with not only robust, high quality antibodies, but it also links EagleBio to a niche market for the detection of small molecules in cells, tissues, and biological fluids.” Keefe added, “There are so many small molecules that could serve as potential drug targets but have yet to be studied in this way. We certainly plan to stay abreast of the developments in the ImmuSmol pipeline and continue to offer new products in emerging areas of research.”

These products are currently for research use only. Check out the list of new ImmuSmol antibodies below, visit the Eagle website www.EagleBio.com, or call 866-411-8023 for full details.

 

 

L-Tryptophan mouse Monoclonal Antibody

L-Kynurenine mouse Monoclonal Antibody

L-Kynurenine rabbit Polyclonal Antibody

Kynurenic acid mouse Monoclonal Antibody

Kynurenic acid rabbit Polyclonal Antibody

Quinaldic acid mouse Monoclonal Antibody

Quinaldic acid rabbit Polyclonal Antibody

Anthranilic acid mouse Monoclonal Antibody

Anthranilic acid rabbit Polyclonal Antibody

3-HydroxyAnthranilic acid mouse Monoclonal Antibody

3-HydroxyAnthranilic acid rabbit Polyclonal Antibody

Quinolinic acid mouse Monoclonal Antibody

Quinolinic acid rabbit Polyclonal Antibody

Picolinic acid rabbit Polyclonal Antibody

Cinnabarinic acid mouse Monoclonal Antibody

Xanthurenic acid mouse Monoclonal Antibody

Xanthurenic acid rabbit Polyclonal Antibody

Dopamine rabbit Polyclonal Antibody

3-Methoxytyramine rabbit Polyclonal Antibody

GABA rabbit Polyclonal Antibody

Serotonin rabbit Polyclonal Antibody

Melatonin rabbit Polyclonal Antibody

5-HIAA rabbit Polyclonal Antibody

L-Glutamate rabbit Polyclonal Antibody

 

L-Glutamate mouse Monoclonal Antibody

 

D-Serine rabbit Polyclonal Antibody

L-Serine rabbit Polyclonal Antibody

 

 

 



The utility of circulating LHCGR as a predictor of Down’s syndrome in early pregnancy


Abstract

Background
Previous studies showed that soluble LHCGR/hCG-sLHCGR concentrations in serum or plasma combined with PAPP-A and free βhCG significantly increased the sensitivity of Down’s syndrome screen at early pregnancy without altering the false positive rate. The goal of the present study was to further examine the role of sLHCGR forms as combinatorial markers and to investigate whether sLHCGR could serve as an independent biomarker for Down’s syndrome in first trimester pregnancy screens.

Methods
The PAPP-A, free βhCG, and hCG-sLHCGR concentrations together with nuchal translucency (NT) were measured in 40 Down’s and 300 control pregnancies. The sLHCGR concentration was analysed in 40 Down’s and 206 control pregnancies.

Results
The hCG-LHCGR in combination with PAPP-A and free βhCG increased the detection rate (DR) by 35% without altering the false positive rate (FPR). The sLHCGR: hCG-sLHCGR ratio alone detected 80% of Down’s pregnancies in first trimester screening, with a false positive rate of 0.5%.

Conclusions
While measurement of sLHCGR forms in combination with PAPP-A and free βhCG significantly increases the detection rate of Down’s syndrome at first trimester, the ratio of sLHCGR: hCG-sLHCGR acts as an independent marker with a detection rate that is significantly higher than the existing biochemical markers individually for prenatal first trimester screening of Down’s syndrome.

Keywords:
hCG Receptor; sLHCGR; hCG-LHCGR; ELISA; Down’s syndrome; Prenatal diagnosis; Screening test; Noninvasive prenatal test (NIPT); Early pregnancy

See full details at BioMed Central: 

https://www.biomedcentral.com/1471-2393/14/197